目的 探讨参龙宁心胶囊联合盐酸索他洛尔片治疗室性早搏的临床疗效。方法 选取2018年8月—2021年4月在郑州市中心医院就诊的108例室性早搏患者，按照随机数字表法将全部患者分为对照组和治疗组，每组各54例。对照组口服盐酸索他洛尔片，80 mg/次，1次/d。治疗组在对照组治疗的基础上口服参龙宁心胶囊，2.0 g/次，3次/d。两组患者连续治疗3个月。观察两组的临床疗效，比较心电图指标、心功能指标和血清指标。结果 治疗后，治疗组总有效率92.59%高于对照组总有效率77.78%（P＜0.05）。治疗后，两组的QT离散度、Tp-e间期、室早总数均显著降低（P＜0.05）；治疗组的QT离散度、Tp-e间期、室早总数低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组的左室射血分数（LVEF）显著升高，左心室收缩末内径（LVESD）、左心房内径（LAD）显著降低（P＜0.05）；治疗后治疗组的LVEF高于对照组，LVESD、LAD低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组的N前端脑钠肽（NT-proBNP）、抗心磷脂抗体（ACA）水平显著降低，载脂蛋白A1（ApoA1）水平显著升高（P＜0.05）；治疗后治疗组的NT-proBNP、ACA水平均低于对照组，ApoA1水平高于对照组（P＜0.05）。结论 参龙宁心胶囊联合盐酸索他洛尔片治疗室性早搏的疗效确切，能减轻室性早搏症状，改善心功能，减轻室性早搏患者的心肌损伤。

Objective To investigate the clinical efficacy of Shenlong Ningxin Capsules combined with Sotalol Hydrochloride Tablets in treatment of ventricular premature beat. Methods Patients (108 cases) with ventricular premature beat in Zhengzhou Central Hospital from August 2018 to April 2021 were divided into control and treatment groups according to random number table method, and each group had 54 cases. Patients in the control group were po administered with Sotalol Hydrochloride Tablets, 80 mg/time, once daily. Patients in the treatment group were po administered with Shenlong Ningxin Capsules on the basis of the control group, 2.0 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and electrocardiographic index, cardiac function, and serum index in two groups were compared. Results After treatment, the total effective rate of the treatment group (92.59%) was higher than that of the control group (77.78%) (P < 0.05). After treatment, the QT dispersion, Tp-e interval, and total number of ventricular premature beats in two groups were significantly decreased (P < 0.05). The QT dispersion, Tp-e interval, and total number of ventricular premature beats in the treatment group were lower than those in the control group (P < 0.05). After treatment, the LVEF in two groups were significantly increased, but the LVESD and LAD in two groups were significantly decreased (P < 0.05). After treatment, the LVEF in the treatment group was higher than that in the control group, but the LVESD and LAD were lower than that in the control group (P < 0.05). After treatment, the levels of NT-proBNP and ACA in two groups were significantly decreased, but the level of ApoA1 in two groups were significantly increased (P < 0.05). After treatment, the levels of NT-proBNP and ACA in the treatment group were lower than those in the control group, but the level of ApoA1 in the treatment group was higher than those in the control group (P < 0.05). Conclusion Shenlong Ningxin Capsules combined with Sotalol Hydrochloride Tablets is effective in treatment of ventricular premature beat, can reduce the symptoms of ventricular premature beat, improve cardiac function, and reduce the myocardial injury.

R972

河南省医学科技攻关计划联合共建项目(LHGJ20191043)